Revenue: As of FY2025, the actual value is USD 37.06 M, missing the estimate of USD 37.07 M.EPS: As of FY2025, the actual value is USD -0.13.EBIT: As of FY2025, the actual value is USD -12.14 M.<h4>Revenue</h4>Cytosorbents Corporation reported total product revenue of $37.1 million for the year ended December 31, 2025, an increase of 4.1% compared to $35.6 million in 2024, though it was down 0.4% on a constant currency basis. In 2025, direct sales in the United States were $249 thousand, in Germany were $11,751 thousand, and in all other countries were $8,603 thousand. Distributor and strategic partner sales in all other countries amounted to $16,460 thousand in 2025. For 2024, direct sales in the United States were $115 thousand, in Germany were $13,050 thousand, and in all other countries were $7,616 thousand. Distributor and strategic partner sales in the United States were $36 thousand and in all other countries were $14,778 thousand in 2024. Germany contributed approximately 32% of net product sales in 2025. Cumulative sales of CytoSorb reached approximately $285.3 million from late 2011 through December 31, 2025. <h4>Gross Profit</h4>Gross profit increased by 6.4% to $26.5 million in 2025, up from $24.9 million in 2024. The gross margin improved to 71.5% in 2025 from 69.9% in 2024. <h4>Operating Expenses</h4>Research and development expenses decreased by 33.2% to $5.1 million in 2025 from $7.6 million in 2024. Selling, general and administrative expenses increased by 5% to $35.6 million in 2025 from $33.7 million in 2024. Restructuring expenses were $0.5 million in 2025, compared to no such expenses in 2024. Total operating expenses were $41.2 million in 2025 and $41.3 million in 2024. <h4>Loss from Operations</h4>Loss from operations improved by 10.4%, decreasing to - $14.7 million in 2025 from - $16.5 million in 2024. <h4>Other Income (Expense)</h4>Net interest expense increased to - $2.6 million in 2025 from - $1.4 million in 2024. The company reported a gain on foreign currency transactions of $9.3 million in 2025, a significant change from a - $4.2 million loss in 2024. Loss on abandoned patents was - $0.6 million in 2025, up from - $0.3 million in 2024. Total other income (expense), net, was $6.1 million in 2025 compared to - $6.0 million in 2024. <h4>Net Loss and Income Taxes</h4>Net loss for 2025 was - $8.2 million, a substantial improvement from - $20.7 million in 2024. The benefit from income taxes was $0.4 million in 2025, down from $1.7 million in 2024. <h4>Cash Flow</h4>Net cash used in operating activities was - $12.4 million in 2025, an improvement from - $14.4 million in 2024. Net cash used in investing activities was - $0.4 million in 2025, compared to - $0.7 million in 2024. Net cash provided by financing activities was $9.3 million in both 2025 and 2024. The cash burn (total cash used in operating and investing activities) was - $12.8 million in 2025 and - $15.1 million in 2024. Total cash, cash equivalents, and restricted cash at December 31, 2025, was $7.8 million, including $6.3 million in unrestricted cash and $1.5 million in restricted cash. <h4>Outlook/Guidance</h4>Cytosorbents Corporation initiated a strategic workforce and cost reduction plan in Q4 2025, reducing its workforce by approximately 10% and realigning operating and production expenses. The company anticipates reaching operating cash flow break-even in the second half of 2026. An update on the anticipated timing for a new De Novo submission for DrugSorb-ATR to the FDA is expected once interactive discussions on final requirements are complete.

CytoSorbents | 10-K: FY2025 Revenue Misses Estimate at USD 37.06 M